Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jing Wang
Institutions:
Tianjin Medical University General Hospital,
Tianjin Medical University
Observed institutions:
Tianjin Medical University General Hospital,
Tianjin Medical University Cancer Institute and Hospital,
Tianjin Medical University
ORCID:
0000-0003-2588-0481
Observed ORCID:
0000-0003-2588-0481
OpenAlex ID:
A5072319168
Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study
2023
·
Linlin Zhang
, Liuchun Wang
, et al.
·
Molecular Cancer
·
20
PDF
Microbiome-metabolome dysbiosis of bronchoalveolar lavage fluid of lung cancer patients
2025
·
Jing Wang
, Wei Su
, et al.
·
Frontiers in Microbiology
·
5
Bevacizumab/PD-1 inhibitor plus chemotherapy as first-line treatment of advanced non-squamous non-small-cell lung cancer
2023
·
Jing Wang
, Qin Chen
, et al.
·
Journal of Comparative Effectiveness Research
·
2
ATR inhibition potentiates immunotherapy efficacy via TBK1-NFκB signaling and autophagy blockade in non-small cell lung cancer
2026
·
Guo Li
, Lingping Kong
, et al.
·
Cancer Immunology Immunotherapy
Show more works
View as search
Works count:
4
Citation count:
27
H-index:
2
I10-index:
1
Year
Topic
Type